Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by symmetric polyarticular synovial inflammation that produces pain, stiffness (especially morning stiffness lasting more than 1 hour), swelling, and, without adequate treatment, joint destruc… Read more.
2 factors with evidence, ordered from most to least effective. Information, not medical advice.
⏱ 2 min read
Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by symmetric polyarticular synovial inflammation that causes pain, stiffness (especially morning stiffness lasting more than 1 hour), swelling, and, without adequate treatment, progressive joint destruction with deformity and disability; it affects approximately 1% of the adult population, with a female predominance. It is a disease whose prognosis has changed radically in recent decades thanks to traditional disease-modifying antirheumatic drugs (DMARDs) and especially to biologics and new targeted therapies.
Methotrexate remains the first-line traditional DMARD, often combined with others (sulfasalazine, hydroxychloroquine, leflunomide).
Biologics: anti-TNF (etanercept, adalimumab, infliximab), anti-IL-6 (tocilizumab, sarilumab), anti-CD20 (rituximab), anti-CTLA-4 (abatacept), among others.
JAK inhibitors (tofacitinib, baricitinib, upadacitinib): oral agents with efficacy comparable to biologics.
Corticosteroids: at low doses as a bridge or during flares.
NSAIDs: symptomatic relief.
The modern treatment goal is clinical remission or, failing that, low disease activity, assessed with standardized indices (DAS28, SDAI, CDAI).
Mediterranean diet: supported by cohorts and some trials for reducing inflammatory activity and possibly preventing onset.
Omega-3 EPA/DHA (2-4 g/day): a documented adjunctive anti-inflammatory effect in meta-analyses; a modest but significant reduction in morning stiffness, joint pain, and NSAID need.
Smoking cessation: smoking is an important risk factor for developing RA and is associated with a poorer response to treatment.
Adapted physical exercise: combines cardiovascular work, strength, and mobility. Improves function, pain, stiffness, fatigue, and cardiovascular comorbidities.
Weight control: obesity worsens symptoms and response to treatment.
Stress management: stress can precipitate flares.
Adequate sleep: poor sleep quality increases pain perception.
Curcumin (with good bioavailability: piperine, phytosomes): supported by meta-analyses for reducing RA activity, comparable to some NSAIDs in small studies.
Boswellia serrata: modest support.
Borage or evening primrose oil (GLA): modest support in meta-analyses.
Vitamin D: deficiencies are very common in RA; correction is reasonable.
Specific probiotics: growing support via the microbiota-immunity axis.
Green tea EGCG: extensive preclinical support, preliminary clinical data.
RA increases the risk of: - Cardiovascular disease (chronic systemic inflammation accelerates atherosclerosis). - Osteoporosis (from inflammation + corticosteroids + reduced activity). - Infections (from immunosuppression). - Specific cancers (lymphoma). - Depression.
Controlling inflammation with appropriate treatment reduces these risks.
Joint pain with morning stiffness lasting longer than 30-60 minutes, joint swelling without trauma, symmetric involvement of several joints (hands, feet, wrists), unexplained fatigue, and risk factors (young or middle-aged woman, family history, smoking) require early rheumatological evaluation. Early diagnosis and prompt initiation of DMARDs change the prognosis substantially; the “window of opportunity” in the first months is key.
Rheumatoid arthritis requires specialized medical treatment (traditional DMARDs and/or biologics depending on severity), started as early as possible. Nutrition (Mediterranean diet, omega-3), adapted physical exercise, weight control, and smoking cessation are important complements with clinical support. Anti-inflammatory supplements (curcumin, boswellia, GLA, vitamin D) can provide a modest adjunctive benefit. The goal is sustained remission or low disease activity to preserve joint function and prevent comorbidities.
⏱ 2 min read
Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by symmetric polyarticular synovial inflammation that causes pain, stiffness (especially morning stiffness lasting more than 1 hour), swelling, and, without adequate treatment, progressive joint destruction with deformity and disability; it affects approximately 1% of the adult population, with a female predominance. It is a disease whose prognosis has changed radically in recent decades thanks to traditional disease-modifying antirheumatic drugs (DMARDs) and especially to biologics and new targeted therapies.
Methotrexate remains the first-line traditional DMARD, often combined with others (sulfasalazine, hydroxychloroquine, leflunomide).
Biologics: anti-TNF (etanercept, adalimumab, infliximab), anti-IL-6 (tocilizumab, sarilumab), anti-CD20 (rituximab), anti-CTLA-4 (abatacept), among others.
JAK inhibitors (tofacitinib, baricitinib, upadacitinib): oral agents with efficacy comparable to biologics.
Corticosteroids: at low doses as a bridge or during flares.
NSAIDs: symptomatic relief.
The modern treatment goal is clinical remission or, failing that, low disease activity, assessed with standardized indices (DAS28, SDAI, CDAI).
Mediterranean diet: supported by cohorts and some trials for reducing inflammatory activity and possibly preventing onset.
Omega-3 EPA/DHA (2-4 g/day): a documented adjunctive anti-inflammatory effect in meta-analyses; a modest but significant reduction in morning stiffness, joint pain, and NSAID need.
Smoking cessation: smoking is an important risk factor for developing RA and is associated with a poorer response to treatment.
Adapted physical exercise: combines cardiovascular work, strength, and mobility. Improves function, pain, stiffness, fatigue, and cardiovascular comorbidities.
Weight control: obesity worsens symptoms and response to treatment.
Stress management: stress can precipitate flares.
Adequate sleep: poor sleep quality increases pain perception.
Curcumin (with good bioavailability: piperine, phytosomes): supported by meta-analyses for reducing RA activity, comparable to some NSAIDs in small studies.
Boswellia serrata: modest support.
Borage or evening primrose oil (GLA): modest support in meta-analyses.
Vitamin D: deficiencies are very common in RA; correction is reasonable.
Specific probiotics: growing support via the microbiota-immunity axis.
Green tea EGCG: extensive preclinical support, preliminary clinical data.
RA increases the risk of: - Cardiovascular disease (chronic systemic inflammation accelerates atherosclerosis). - Osteoporosis (from inflammation + corticosteroids + reduced activity). - Infections (from immunosuppression). - Specific cancers (lymphoma). - Depression.
Controlling inflammation with appropriate treatment reduces these risks.
Joint pain with morning stiffness lasting longer than 30-60 minutes, joint swelling without trauma, symmetric involvement of several joints (hands, feet, wrists), unexplained fatigue, and risk factors (young or middle-aged woman, family history, smoking) require early rheumatological evaluation. Early diagnosis and prompt initiation of DMARDs change the prognosis substantially; the “window of opportunity” in the first months is key.
Rheumatoid arthritis requires specialized medical treatment (traditional DMARDs and/or biologics depending on severity), started as early as possible. Nutrition (Mediterranean diet, omega-3), adapted physical exercise, weight control, and smoking cessation are important complements with clinical support. Anti-inflammatory supplements (curcumin, boswellia, GLA, vitamin D) can provide a modest adjunctive benefit. The goal is sustained remission or low disease activity to preserve joint function and prevent comorbidities.